Trials / Completed
CompletedNCT01833494
A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 161 (actual)
- Sponsor
- Kissei Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the safety and efficacy for 52-week dosing in hemodialysis patients with hyperphosphatemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PA21 |
Timeline
- Start date
- 2013-03-18
- Primary completion
- 2014-08-01
- Completion
- 2014-08-04
- First posted
- 2013-04-17
- Last updated
- 2018-10-09
- Results posted
- 2018-10-09
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01833494. Inclusion in this directory is not an endorsement.